CooperCompanies (COO) Q4 2025 earnings review
Execution Drives Beat & Strong Guidance; Strategic Review Takes Center Stage
CooperCompanies reported a solid Q4, beating revenue and EPS expectations for the eighth consecutive quarter. Non-GAAP EPS grew 11% YoY, driven by significant operating expense leverage from a major Q4 reorganization that is expected to deliver $50 million in annual savings. While underlying organic revenue growth decelerated in the second half of FY25, management issued a confident FY26 outlook for re-accelerating sales and continued earnings growth, supported by new contract wins for its premium MyDay contact lenses. However, the operational results were accompanied by a major announcement of a formal strategic review and a new Board Chair, signaling potential significant changes ahead and making it the focal point for investors.
🐂 Bull Case
The company continues to deliver strong profitability, beating EPS estimates for the eighth straight quarter. A Q4 reorganization is set to deliver $50M in annual savings, fueling a strong FY26 EPS guide ($4.45 - $4.60) and showcasing disciplined cost management.
Management raised its long-term free cash flow target, now expecting to generate over $2.2 billion from FY26 through FY28. This provides substantial capacity for the ongoing $2 billion share repurchase program and debt reduction.
Management reported winning 'quite a few more' contracts for its premium MyDay contact lenses in Q4, setting the stage for CooperVision's revenue growth to re-accelerate in FY26 after a soft patch in late FY25.
🐻 Bear Case
Consolidated organic revenue growth decelerated sharply from 7% in Q2 to 2-3% in the second half of FY25. While guidance is optimistic, the company must reverse this trend to justify its growth narrative.
The Fertility business remains a drag on growth, posting just 1% organic growth in Q4. This follows several quarters of low-single-digit performance, questioning the timeline for a meaningful rebound.
The announcement of a formal strategic review creates significant uncertainty. While it could unlock value, it could also lead to management distraction, disruptive changes, or a lengthy period with no clear outcome.
⚖️ Verdict: 🟢
Bullish. While the top-line deceleration and Fertility weakness are valid concerns, the company's operational execution is impressive. The ability to drive double-digit earnings growth through cost discipline, coupled with a robust FCF outlook and aggressive share buybacks, provides a strong financial foundation. The strategic review, while creating uncertainty, signals a proactive approach to maximizing shareholder value.
Key Themes
Reorganization Unlocks Profitability
The company completed a significant reorganization in Q4, incurring an $89 million charge. This initiative is expected to generate approximately $50 million in annual pre-tax savings starting in FY26. Management cited leveraging prior IT investments and AI capabilities to integrate support functions and reduce back-office costs. This cost-saving program is the primary driver behind the strong FY26 non-GAAP EPS guidance and demonstrates a successful shift towards improving operational leverage.
Capital Return Program in Focus
CooperCompanies accelerated its capital return, repurchasing $197.3 million of stock in Q4 alone. With nearly $1 billion remaining on its authorization and a stated goal to allocate roughly two-thirds of FY26 free cash flow to buybacks, this has become a core part of the value proposition. The newly announced strategic review explicitly states that during the review period, the company will focus capital deployment on repurchases.
Fertility Segment Remains a Laggard
The CooperSurgical Fertility business continues to underperform, reporting just 1% organic growth. This is a continuation of a weak trend (Q2: +2%, Q3: +3%). Management remains optimistic about a stronger FY26, citing new RFP wins and interest in new technology, but acknowledges that consumer spending remains tight and clinics are managing spending carefully. The segment's continued weakness is a drag on overall corporate growth.
Formal Strategic Review Initiated
Concurrent with earnings, the company announced a formal strategic review to identify opportunities to enhance long-term shareholder value. The review will consider partnerships, divestitures, mergers, and other transactions. This move, along with the appointment of a new Board Chair, follows an evaluation of alternatives that began earlier in the year and will now be the dominant narrative for the stock.
Myopia Management (MiSight) Accelerates
MiSight delivered strong growth of 37% in Q4, with robust performance in the Americas and a record quarter in EMEA. For the full year, MiSight sales reached $104 million, up 30%. Management guided for at least 20-25% growth in FY26, supported by upcoming launches of MiSight in Japan and the premium MyDay MiSight lens in Europe, both scheduled for Q2'26.
Data Contradicts Narrative: Organic Growth Decelerated Sharply in H2'25
While management highlighted a strong quarter, the underlying data shows a significant slowdown. Consolidated organic revenue growth fell from 7% in Q2 to just 2% in Q3 and 3% in Q4. This deceleration was driven by CooperVision's growth slowing from 7% to 2-3% in the same period. While guidance points to a recovery, the trend entering FY26 is weak and reliant on a sharp turnaround.
Other KPIs
The company generated $149.8 million in FCF in Q4, bringing the full-year total to $433.7 million. Management's guidance for FY26 is a significant step-up to $575-$625 million, as a major CapEx investment cycle for CooperVision winds down. This underpins the company's ability to fund its aggressive share repurchase program.
The quarter highlights a key dynamic: non-GAAP gross margin contracted by 70 bps to 66% due to tariffs and unfavorable product mix. However, non-GAAP operating margin expanded by 110 bps to 27.0% due to strong operating expense control, a trend expected to continue into FY26 as reorganization savings are realized.
The Asia Pacific region for the core contact lens business was flat year-over-year, following a 5% decline in Q3. Management cited a 28% decline in China, driven by weakness in low-margin e-commerce channels where the company is avoiding aggressive pricing. This region remains a significant headwind to CVI's overall growth.
Guidance
Accelerating. The midpoint of guidance implies organic growth of 5.0%. This represents an acceleration from the 3.4% organic growth delivered in Q4 and the 4% organic growth for the full-year FY25, indicating management's confidence in new contract wins and improving market dynamics.
Decelerating growth. The midpoint ($4.525) implies 9.6% YoY growth. While strong, this is a deceleration from the 12% growth achieved in FY25. This suggests that while reorganization savings provide a significant boost, the company faces tougher comps and moderating leverage.
Stable. The guidance for 3% to 4% organic growth is consistent with the 3.4% achieved in Q4'25, but represents a continued deceleration from the 5% organic growth in Q1'25. Management described this as a continued 'stair step' higher from recent performance.
Accelerating growth. The midpoint ($1.03) implies 12% YoY growth, an acceleration from the 8% growth in Q1'25, reflecting the immediate impact of cost-saving initiatives and operating leverage.